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is within expected limits due to RF ablation is known immediately 
post procedure, but the expected levels at longer follow-up times are 
not well described, though such information may be important both 
as a marker for the extent of ablation and in the evaluation of post-
procedure chest pain [5].
Methods
A prospective cohort of 31 patients undergoing curative AF 
Ablation had a single tI level (Beckman-Coulter) drawn the day 
following the procedure. A tI level of <0.04ng/mL was considered 
normal by the laboratory, 0.04 ng/mL to <0.06ng/mL considered 
suggestive of cardiac damage, and >0.5ng/mL considered consistent 
with myocardial infarction.  The upper reference limit was 0.04ng/
mL.  Clinical variables were also collected, such as ablation type 
and radiofrequency (RF) time.  Basic demographic information, 
RF parameters, tI level, and AF ablation outcomes were recorded. 
Results are expressed as mean ± standard deviation, unless otherwise 
noted.  Discrete variables were compared across patient groups 
using the Chi-Square, Fisher, or Spearman tests where appropriate. 
Continuous variables were compared with Student’s t-test or Mann-
Whitney tests, where appropriate.  A two-tailed p-value <0.05 was 
considered statistically significant.  All analysis was performed using 
SPSS 16.0 (SPSS Inc, Chicago, IL).
Results
The average age in this patient population was 56.9 ± 10.9 years. 
Paroxysmal AF was present in 23 patients, and 8 had chronic AF. 
Patients were generally healthy with no patients with severe heart 
failure, LV dysfunction/cardiomyopathy, or renal failure.  Patients 
underwent linear wide-area circumferential ablation (WACA) with 
additional linear lesions (roof and mitral) (n=18), WACA plus 
segmental pulmonary vein isolation (PVI) (n=7), or PVI only (n=6). 
The average RF time was 2627.8 ± 737.5 seconds.  The mean RF power 
was 61.7 ± 4.3W (range 55-70W). The mean RF temperature limit 
was 53.6 ± 2.0 ºC (range 50-55°C). The most commonly used ablation 
Abstract
Background: The range of elevation of troponin I (tI) that is within 
expected limits from left atrial radiofrequency ablation for atrial 
fibrillation (AF) is not well described, though such information may 
be of clinical value.
Objectives: Identify the expected range of tI values post-atrial 
fibrillation (AF) ablation.
Methods: 31 patients undergoing AF ablation had a single tI level 
drawn the day following the procedure.  Clinical variables were also 
collected, such as ablation type and radiofrequency (RF) time.
Results:  Paroxysmal AF was present in 23 patients, and 8 had 
chronic AF.  The average RF time was 2627.8 ± 737.5 seconds. 
The mean RF power was 61.7 ± 4.3W (range 55-70W). The mean 
RF temperature limit was 53.6 ± 2.0°C (range 50-55°C).  There was 
no clinical or electrocardiographic evidence of coronary ischemia 
in this population.  The mean tI the following day was 3.21 ± 1.5 
(range 1.48-8.41).  There was no correlation between RF time, 
ablation type, ablation catheter size, and ablation temperature or 
ablation power and tI levels.
Conclusions: Troponin I elevation post-ablation was ubiquitous. 
Knowledge of expected post-ablation tI levels may be helpful in the 
evaluation of post-procedure chest pain.
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Introduction
Left atrial radiofrequency (RF) ablation is an established 
procedure for the treatment of atrial fibrillation (AF) [1,2] and is 
increasingly being applied in the AF population.  Cardiac RF ablation 
causes myocardial necrosis that can be detected through the use of 
cardiac enzyme markers such as troponin I (tI) [3,4].  Troponin 
I levels peak at 12 to 16 hours and may remain elevated for up to 
two weeks after myocardial injury.  The range of elevation of tI that 
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catheter tip size was 8mm (81.2% of cases), with 9.4% cases using 
standard 4mm tips and 6.2% using both 8mm and 4mm ablation 
catheters.  There was no clinical or electrocardiographic evidence of 
coronary ischemia in this population.  The mean tI the following day 
was 3.21 ± 1.5 (range 1.48-8.41).  There was no correlation between 
RF time (p=0.459), ablation temperature (p=0.888) or ablation power 
(p=0.275) and tI levels (Figure 1).  Ablation type (p=0.431) nor 
ablation catheter size (p=0.620) was predictive of tI levels.
All patients (100 %) had tI levels above both the upper reference 
limit (0.04ng/mL) and the upper limit of normal in our laboratory 
(>0.5ng/mL).  The lowest recorded tI was more than double the upper 
limit of normal.  The extent of tI elevation was not predictive of AF 
ablation success rates (CI 0.507–1.418, p=0.53) (Figure 2).
Discussion
The primary finding of this study is that troponin I elevations 
in the diagnostic range for myocardial infarction are ubiquitous 1 
day after AF ablation, with a mean value of 3.21 (6.4 times the local 
laboratory cutoff for myocardial infarction).  The main value of these 
data on tI elevations after AF ablation are to provide a reasonable 
reference range of what may be expected quantitatively in terms of tI. 
Clinicians assessing a patient with chest pain shortly following an AF 
ablation may find this of value for medical decision making.
These values were obtained in a younger population of patients 
typical of an AF ablation cohort without major comorbidities.  These 
values would be inconsistent with any small release of troponin 
due to recent rapid ventricular rates in AF prior to ablation, which 
was not an issue in the study population.  None of our patients had 
severe heart failure or renal failure to account for chronic troponin 
elevations.
Prior published reports on troponin elevation after AF ablation 
have only looked at the immediate time period post-ablation.  Haegeli 
et al. [5] examined troponin T levels 4 hrs post-ablation using a 4 
mm ablation catheter in 60 patients, and found the mean troponin 
T to be 0.85ng/mL (5.7 times local laboratory cutoff for myocardial 
infarction).  The degree of elevation did not correlate with common 
ablation parameters, such as ablation strategy or RF time.  Post-
ablation chest pain is a common complaint in this patient population, 
and physicians commonly rely on cardiac enzymes to determine the 
clinical significance of these symptoms.  The time period of 4 hours in 
Haegeli et al. is likely not long enough to reflect peak levels, and may 
under-represent the level of troponin that is to be expected following 
ablation. While our data examined troponin I, the levels found (3.21 
± 1.5ng/mL, range 1.48-8.41) were comparably slightly higher.  These 
levels, while elevated, are an expected product of AF ablation and 
some reference values for clinical management would be of assistance 
in evaluating patients with chest pain after AF ablation.
Chest pain after AF ablation is generally not associated with 
ischemia, but for other reasons such as pericarditis.  Knowledge of the 
expected range of troponin elevation following AF ablation should 
be helpful and may assist clinicians in the evaluation of chest pain 
shortly after AF ablation.  For example, values of troponin markedly 
more than seen in this study could suggest non-AF ablation-related 
chest pain such as myocardial ischemia which can occur in left atrial 
procedures [6].
Limitations
These data are limited by the small sample size and thus may not 
reflect the full range of values.  A larger sample may have provided a 
greater range.  In addition, only a single troponin value was available, 
so it was not possible to analyze tI values over time or to compare 
them from baseline.  Furthermore, the range of expected values from 
irrigated tip catheters or cryoballoon ablation may vary and were not 
assessed in this study.
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Figure 1: The correlation between RF ablation duration and following-day 
troponin I elevation.
         
Figure 2: The relationship between the following-day troponin I elevation and 
long-term clinical success of the atrial fibrillation ablation.
